J Pediatric Infect Dis Soc. 2024 Jul 27:piae076. doi: 10.1093/jpids/piae076. Online ahead of print.
ABSTRACT
We characterised population pharmacokinetics in 42 African children receiving once-daily 25 mg (14-<20 kg) or 50 mg (>20 kg) dolutegravir. Co-administration with emtricitabine and tenofovir alafenamide reduced dolutegravir bioavailability by 19.6% (95%CI: 8.13-30.8%) compared to zidovudine or abacavir with lamivudine. Nevertheless, concentrations remained above efficacy targets, confirming current dosing recommendations.
PMID:39066509 | DOI:10.1093/jpids/piae076
